Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Neurocomputational Dynamics of Cooperation (COBRA)

6 agosto 2026 aggiornato da: Timothy Allen, University of Pittsburgh
The purpose of this study is to understand brain function, how people make decisions when they interact with others, and how brain function and behavior relate to personality traits.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Problems in cooperating with others define antagonism, a transdiagnostic dimension of psychopathology expressed in personality and externalizing disorders. People high on antagonism are prone to aggressive, callous, and exploitative behaviors that damage relationships and incur substantial costs in the form of productivity loss, substance misuse, and criminality. While clinical theories link antagonism to deficits in social cognition, it is hard to deny that exploiting others requires an understanding of their mind. This apparent contradiction can be resolved by distinguishing between two facets of antagonism: callousness and exploitativeness. Prior work by the investigators and preliminary data inform the hypothesis that exploitativeness reflects an enhanced capacity to learn about the mental states and behaviors of others coupled with an increased sensitivity to personal, rather than shared, rewards. In contrast, callousness reflects a broader insensitivity to social feedback. The investigators hypothesize that these dissociable social learning processes are instantiated in canonical circuits that expanded during anthropogenesis to support mentalizing and self-directed thought. These learning signals, which track behaviorally salient features of the social environment, are integrated in the posterior hub of the default network (DN) where they drive adaptive cooperation. This study proposes to test these hypotheses in two samples elevated on antagonism. At the behavioral level, participants are characterized using a battery of personality and psychopathology measures, social and reward-based decision-making tasks, and corresponding hierarchically estimated reinforcement learning (RL) models (Aim 1). In a model-based functional magnetic resonance imaging (fMRI) study, model-derived learning signals and facets of antagonism are linked to underlying neural activity during cooperative decision-making (Aim 2). Leveraging the multi-timescale design of our study, the investigators plan to relate neurocomputational signatures of callousness and exploitativeness to mentalizing abilities, multi-informant reports of momentary interpersonal behavior, and prospective stress generation. Certain elements of study design are withheld from this record to protect the scientific integrity of the study design.

Tipo di studio

Interventistico

Iscrizione (Stimato)

1612

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Michelle M Berry, MPS
  • Numero di telefono: 424-380-1194
  • Email: berrymic@pitt.edu

Backup dei contatti dello studio

Luoghi di studio

  • Stati Uniti
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • University of Pittsburgh, Bellefield Towers
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Timothy A Allen, PhD
        • Sub-investigatore:
          • Alexandre Dombrovski, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Online cohort inclusion criteria:

  • English fluency
  • US residency
  • Owner of a desktop or laptop computer
  • Adult aged 18-100

Online cohort exclusion criteria:

  • Participants who have participated in an earlier version of the study
  • Inability to consent
  • Self-reported history of neurological disorder or brain damage
  • Self-endorsed history of psychosis or mania

Clinical cohort inclusion criteria:

  • Adult aged 20-60 years old
  • English fluency
  • Owner of a smartphone with celluar data

Clinical cohort exclusion criteria:

  • Inability to consent
  • Self-reported history of neurological disorder or brain damage
  • Clinician-rated psychosis or mania in the last 6 months
  • Current intoxication or withdrawal
  • Estimated IQ < 70
  • fMRI safety concerns
  • Pregnancy
  • Lack of stable psychiatric treatment (e.g., medication dosage, therapy modality) for the previous two months

Informant inclusion criteria:

  • Adult aged 18+ years old
  • English fluency
  • Owner of a smartphone with celluar data
  • Must have 4+ interactions/week with the participant for at least 6 months prior to study baseline

Informant exclusion criteria:

- Lack of a smartphone with cellular data at study baseline

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Online Cohort
The online cohort will include 718 adults ages 18-100 who will complete 1) a battery of behavioral tasks designed to assess social learning and mentalizing abilities, and 2) self-report measures assessing personality, externalizing symptoms, interpersonal functioning, and psychopathology.
Comportamentale: Social Learning Task Battery, Online Cohort
In the primary study task, participants engage in a modified iterative trust game. Participant choices earn feedback in the form of monetary gains or losses. All participants are debriefed on the motivation behind study task at the end of their visit.
Sperimentale: Clinical Cohort
The study will enroll up to 416 clinical-cohort participants, with an anticipated final eligible sample of 239 adults ages 20-60 who will complete 1) a structured clinical interview and neuropsychological assessments, 2) self-report measures assessing personality, externalizing symptoms, interpersonal functioning, and psychopathology, 3) lab-based tasks designed to assess social learning and mentalizing abilities while monitoring physiological responding with Biopac, 4) task-based fMRI, 5) 21-day ecological momentary assessment (EMA) protocol, and 6) additional self-report questionnaires at three yearly follow-ups. The investigators expect to enroll 416 participants for the start of the protocol to yield 239 final eligible participants to complete fMRI and EMA.
Comportamentale: Social Learning Task Battery, Clinical Cohort
In the primary study task, participants engage in a modified iterative trust game. The task is completed in the fMRI scanner and takes about 35 minutes. Participant choices earn feedback in the form of monetary gains or losses. All participants are debriefed on the motivation behind the task at the end of their visit.
Nessun intervento: Informants
Additionally, 2 informants (ages 18+) for each participant will be recruited to complete self-report measures, one of whom will also enroll in EMA.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Participant-level Coaxing Score
Lasso di tempo: During behavioral task visit at study baseline (clinical cohort) or during single online study session (online cohort)
Participant coaxing behavior will be measured during the primary social learning task. Coaxing will be operationalized as the difference in the participant's return rate between exchange and secrecy modes on trials in which the coplayer decides not to share. In exchange mode, the participant knows whether the coplayer chose to share or keep the monetary incentive before indicating whether they would return it. In secrecy mode, the participant must make the return decision before learning the coplayer's choice. The coaxing score is calculated as the exchange-mode return rate minus the secrecy-mode return rate. Scores range from -1 to 1, with positive values indicating greater strategic coaxing and 0 indicating no difference between modes.
During behavioral task visit at study baseline (clinical cohort) or during single online study session (online cohort)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean Informant-rated Momentary Manipulativeness
Lasso di tempo: Post-baseline 21-day EMA period within year 1 of the study
Manipulativeness will be assessed using the study-specific Interpersonal Dynamics EMA Battery. The informant-rated manipulativeness scale contains 3 items, each rated from 1 ("strongly disagree") to 5 ("strongly agree"). At each assessment, responses to the 3 items will be averaged to produce a momentary manipulativeness score that ranges from 1 to 5. Higher scores indicate greater informant-rated manipulativeness.
Post-baseline 21-day EMA period within year 1 of the study
Latent Mentalizing Factor
Lasso di tempo: Baseline
A latent mentalizing factor will be derived using CFA, with participants' scores on three social cognition tasks serving as indicators. The latent factor will be standardized to a mean of 0 and standard deviation of 1 in the study sample and therefore has no fixed theoretical minimum or maximum. Higher factor scores indicate greater mentalizing ability.
Baseline
Interpersonal Stress
Lasso di tempo: At 12, 24, and 36 months after baseline
Interpersonal stress will be assessed using the marital- or partner-relationship and other-relationship life domains of the Stress and Adversity Inventory for Adults. At each follow-up, the frequency scores for stressors in these two domains will be averaged to produce an interpersonal stress score. The score ranges from a minimum of 0 stressors, with no limit on reported stressor maximums. Higher scores indicate more frequent exposure to interpersonal relationship stressors.
At 12, 24, and 36 months after baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

University of Pittsburgh

Collaboratori

National Institute of Mental Health (NIMH)
Emory University
University of Pittsburgh Medical Center

Investigatori

  • Investigatore principale: Timothy A Allen, PhD, University of Pittsburgh

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 settembre 2026

Completamento primario (Stimato)

30 giugno 2031

Completamento dello studio (Stimato)

30 giugno 2031

Date di iscrizione allo studio

Primo inviato

6 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 agosto 2026

Primo Inserito (Effettivo)

12 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • STUDY25050217
  • R01MH140901 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Individual participant data (IPD) will be shared via the National Institute of Mental Health Data Archive (NDA) in accordance with National Institutes of Health (NIH) Data Management and Sharing Policy. Data will be de-identified and made available to qualified researchers upon request after publication of primary results or completion of the study, as outlined in the NIH-approved Data Sharing Plan.

Task code will be posted on GitHub and/or OSF.

Periodo di condivisione IPD

All data will be deposited to NDA starting 12 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates.

IPD and supporting information will be available when the award ends (anticipated 06/30/2031). NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.

Criteri di accesso alla condivisione IPD

Deidentified data will be findable for the research community through the NDA Collection that will be established when this application is funded. For all publications, an NDA study will be created. Each of those studies is assigned a digital object identifier (DOI). This data DOI will be referenced in the publication to allow the research community easy access to the exact data used in the publication.

To request access to the data, qualified researchers will use the standard processes at NDA, and the NDA Data Access Committee will decide which requests to grant. The standard NDA data access process allows access for one year and is renewable.

Tipo di informazioni di supporto alla condivisione IPD

  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi